When comparing PTX with other therapies commonly used for ASCVD prevention in DKD patients, such as statins, angiotensin-converting enzyme (ACE) inhibitors, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, it is important to note that these agents primarily target lipid levels, blood pressure, and glycemic control. The gene discussed is SLC5A2; the disease is diabetic kidney disease.